Related coverage linked through entity extraction aliases.
May 05, 2026
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Mar 05, 2026
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
Feb 22, 2026
AbbVie announced a quarterly cash dividend of $1.73 per share, payable May 15, 2026. The company has increased its dividend by over 330 percent since 2013 and remains an S&P Dividend Aristocrat.
